RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Fibrosarcoma: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Sclerosing epithelioid fibrosarcoma of the bone: a systematic review of radiologic findings and associated clinical features.
Kanaani Nejad Fatemeh et al., Annals of medicine and surgery (2012) (1 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42866766/
- 2.
Sclerosing epithelioid fibrosarcoma of the bone: a systematic review of radiologic findings and associated clinical features
Kanaani Nejad F et al. (8 September 2026)
https://europepmc.org/search?query=Sclerosing%20epithelioid%20fibrosarcoma%20of%20the%20bone%3A%20a
- 3.
Advances and Challenges in the Multidisciplinary Treatment of Retroperitoneal Infantile Fibrosarcoma in Early Life.
Brunetti Gaia et al., European journal of haematology (1 September 2026)
https://pubmed.ncbi.nlm.nih.gov/41846581/
- 4.
Fibrosarcoma of bone masquerading as fibrous dysplasia: diagnostic pitfall and molecular correlates of aggressive behavior.
Shi Wangpan J et al., Journal of pathology and translational medicine (1 September 2026)
https://pubmed.ncbi.nlm.nih.gov/42740340/
- 5.
Primary Bronchial Hybrid Low-Grade Fibromyxoid Sarcoma/Sclerosing Epithelioid Fibrosarcoma With EWSR1::CREB3L1 Fusion: Diagnostic Insights From a Challenging Case in the Respiratory Tract.
Ikeda Hiroko et al., Pathology international (1 September 2026)
https://pubmed.ncbi.nlm.nih.gov/42788956/
Clinical Trials : Australian Sites
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
NCT03899792 · Active (not recruiting) · Phase 1 / Phase 2 · Eli Lilly and Company
Ages 6 Months to 21
https://clinicaltrials.gov/study/NCT03899792
- 2.
Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
NCT00346164 · Completed · Phase 3 · Children's Oncology Group
Up to age 29
https://clinicaltrials.gov/study/NCT00346164
- 3.
Surgery and/or Chemotherapy in Treating Children With Infantile, Congenital, or Childhood Fibrosarcoma
NCT00072280 · TERMINATED · Phase 2 · Children's Oncology Group
Up to age 2
https://clinicaltrials.gov/study/NCT00072280
- 4.
S9624 Ifosfamide in Treating Patients With Meningeal Tumors
NCT00003292 · TERMINATED · Phase 2 · SWOG Cancer Research Network
Ages 18 and over
https://clinicaltrials.gov/study/NCT00003292
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Fibrosarcoma
Fibrosarcoma is a rare cancer that starts in fibroblasts, the cells that make connective tissue. It can arise in soft tissue or, less often, in bone, and most commonly affects the limbs and trunk of adults. Treatment usually involves surgery to remove the tumour, sometimes with radiotherapy or chemotherapy. Research continues into better treatment options.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
BACKGROUND: Primary bone sclerosing epithelioid fibrosarcoma (SEF) is a rare, yet aggressive, condition associated with considerable mortality and prone to misdiagnosis or delayed diagnosis, making precise radiologic identification essential. MATERIALS AND METHODS: The systematic review was conducted in accordance with PRISMA standards. PubMed, Scopus, Web of Science, and Embase were searched through March 2025. The inclusion criteria consisted of English-language human studies with radiologic descriptions of primary bone SEF. Two independent reviewers conducted screening and data extraction. The risk of bias was evaluated utilizing the Joanna Briggs Institute critical appraisal tools for case reports and series. RESULTS: Out of 190 identified papers, 18 met the inclusion criteria, describing 26 patients. The predominant findings in X-rays and computed tomography scans were lysis and destruction (88.46%), well-defined margins (81.81%), and soft tissue involvement (53.84%). magnetic resonance imaging (MRI) data revealed T1-weighted images exhibiting hypo- to isointense signals, while mixed hyper- and hypointense signals mostly characterized T2 sequences. SEF predominantly affected irregular bones (46.2%), followed by long bones (38.5%), with sclerotic rims being most prevalent in long bones (60%). Bone SEF predominantly manifested as pain alone in 40% of cases, and only 33.3% of the patients were initially classified as SEF. Accurate initial diagnosis of SEF was more frequently reported in studies that performed MRI. CONCLUSION: This systematic review elucidates the varied imaging features of bone SEF across several bone types. When these characteristics elicit suspicion in primary imaging, it is probably wise to prioritize MRI, and early biopsy contemplated to guarantee a timely and precise diagnosis.
Common Questions
What is Fibrosarcoma?
Fibrosarcoma is a rare cancer that starts in fibroblasts, the cells that make connective tissue. It can arise in soft tissue or, less often, in bone, and most commonly affects the limbs and trunk of adults. Treatment usually involves surgery to remove the tumour, sometimes with radiotherapy or chemotherapy. Research continues into better treatment options.
How many clinical trials are available for Fibrosarcoma?
RareWays currently indexes 32 clinical trials for Fibrosarcoma, of which 7 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Fibrosarcoma come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Fibrosarcoma.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.